Related Experiment Video
Updated: Feb 25, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
Russell Maxwell1, Christopher M Jackson1, Michael Lim2
1Department of Neurosurgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street Neurosurgery - Phipps 123, Baltimore, MD, 21287, USA.
Opinion Statement:
Immune checkpoint inhibitors have changed the landscape of cancer immunotherapy and are being integrated into the standard of care for a variety of solid and hematologic malignancies. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a grave prognosis despite advances in surgical resection, chemotherapy, and radiation therapy. Implementing immunotherapy for brain tumors mandates additional considerations due to the unique structural and immunologic milieu of the central nervous system (CNS). Nevertheless, strong data from preclinical studies have driven clinical trials of immune checkpoint blockade for newly diagnosed and recurrent GBM. The focus of this review is to discuss the ongoing clinical trials of checkpoint inhibitors in GBM and review the immunologic rationale for ongoing and future trial designs.
Insights
Immune checkpoint inhibitors show promise for glioblastoma (GBM) treatment. This review examines current clinical trials and the scientific basis for using these immunotherapies in brain tumors.
Area of Science:
- Oncology
- Immunology
- Neuro-oncology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy for various malignancies.
- Glioblastoma (GBM) remains a challenging brain tumor with poor outcomes despite standard treatments.
- The central nervous system (CNS) presents unique immunological and structural barriers to immunotherapy.
Purpose of the Study:
- To review ongoing clinical trials of ICIs in GBM.
- To discuss the immunologic rationale supporting ICI use in GBM.
- To inform future clinical trial designs for brain tumor immunotherapy.
Main Methods:
- Review of preclinical data and ongoing clinical trials for ICIs in GBM.
- Analysis of the immunologic landscape of the CNS in the context of cancer.
- Synthesis of information to guide future research and therapeutic strategies.
Main Results:
- Preclinical evidence supports the investigation of ICIs in GBM.
- Clinical trials are actively exploring ICI efficacy in newly diagnosed and recurrent GBM.
- Understanding the CNS immune microenvironment is crucial for optimizing immunotherapy.
Conclusions:
- ICIs represent a promising avenue for GBM treatment, necessitating further clinical investigation.
- The unique CNS environment requires tailored approaches for effective immunotherapy delivery and function.
- Continued research into ICI mechanisms and trial designs is essential for advancing GBM treatment.
